Drug Trial Radar · NCT04315324
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
67
Planned (sponsor's estimate)
Start
Feb 8, 2021
Primary completion
Oct 28, 2025
Study completion Aug 1, 2028
Sponsor
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Mar 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I/II trial studies the safety, side effects and best dose of OBI-3424 and how well it works in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Chemotherapy drugs, such as OBI-3424, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. OBI-3424 may reduce the amount of leukemia in the body.
Conditions
- Recurrent T Acute Lymphoblastic Leukemia
- Refractory T Acute Lymphoblastic Leukemia
- Refractory T Lymphoblastic Lymphoma
- T Lymphoblastic Lymphoma
Interventions
AKR1C3-activated Prodrug AST-3424Drug
Given IV
Biopsy ProcedureProcedure
Undergo biopsy
Biospecimen CollectionProcedure
Undergo blood and CSF sample collection
Bone Marrow AspirationProcedure
Undergo bone marrow aspirate
Computed TomographyProcedure
Undergo CT scan
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD) (Phase I)Time frame: Up to 21 days
- Response rate (complete remission [CR] or CR with incomplete count recovery [CRi]) (Phase II)Time frame: Up to 5 years
Locations
163 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
Kingman Regional Medical Center
Kingman, Arizona
Arkansas Children's Hospital
Little Rock, Arkansas
PCR Oncology
Arroyo Grande, California
City of Hope Comprehensive Cancer Center
Duarte, California
Loma Linda University Medical Center
Loma Linda, California
Children's Hospital of Orange County
Orange, California
Children's Hospital Colorado
Aurora, Colorado
Alfred I duPont Hospital for Children
Wilmington, Delaware
Golisano Children's Hospital of Southwest Florida
Fort Myers, Florida
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Hollywood, Florida
Johns Hopkins All Children's Hospital
St. Petersburg, Florida
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia
Children's Healthcare of Atlanta - Arthur M Blank Hospital
Atlanta, Georgia
Augusta University Medical Center
Augusta, Georgia
Loyola Center for Health at Burr Ridge
Burr Ridge, Illinois
Lurie Children's Hospital-Chicago
Chicago, Illinois
Northwestern University
Chicago, Illinois
University of Illinois
Chicago, Illinois
University of Chicago Comprehensive Cancer Center
Chicago, Illinois
Loyola Medicine Homer Glen
Homer Glen, Illinois
Northwestern Medicine Lake Forest Hospital
Lake Forest, Illinois
Loyola University Medical Center
Maywood, Illinois
Marjorie Weinberg Cancer Center at Loyola-Gottlieb
Melrose Park, Illinois
UC Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois
University of Chicago Medicine-Orland Park
Orland Park, Illinois
Southern Illinois University School of Medicine
Springfield, Illinois
Mary Greeley Medical Center
Ames, Iowa
McFarland Clinic - Ames
Ames, Iowa
McFarland Clinic - Boone
Boone, Iowa
McFarland Clinic - Trinity Cancer Center
Fort Dodge, Iowa
McFarland Clinic - Jefferson
Jefferson, Iowa
McFarland Clinic - Marshalltown
Marshalltown, Iowa
Norton Children's Hospital
Louisville, Kentucky
LSU Health Baton Rouge-North Clinic
Baton Rouge, Louisiana
Our Lady of the Lake Physician Group
Baton Rouge, Louisiana
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland
Bronson Battle Creek
Battle Creek, Michigan
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan
Weisberg Cancer Treatment Center
Farmington Hills, Michigan
Showing 40 of 163 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.